logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Rifamycin S CAS 13553-79-2 for Bacterial Infections

Rifamycin S CAS 13553-79-2 for Bacterial Infections

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 13553-79-2

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15DAY

Payment Terms: L/C,D/A,T/T,D/P,Western Union,MoneyGram

Supply Ability: G,KG,TON

Get Best Price
Highlight:

CAS 13553-79-2 Rifamycin S

,

Rifamycin S

Appearance::
Yellow Orange Crystalline Powder
CAS NO::
13553-79-2
Molecular Formula::
C37H45NO12
Molecular Weight::
695.75300
EINECS NO::
236-938-4
MDL NO::
MFCD06198807
Appearance::
Yellow Orange Crystalline Powder
CAS NO::
13553-79-2
Molecular Formula::
C37H45NO12
Molecular Weight::
695.75300
EINECS NO::
236-938-4
MDL NO::
MFCD06198807
Rifamycin S CAS 13553-79-2 for Bacterial Infections

Product Description:

Product Name: Rifamycin S CAS NO: 13553-79-2  

                    

Synonyms:

O1,O4-didehydro-rifamycin;

NCI 144-130;

1,4-Dideoxy-1,4-dihydro-1,4-dioxorifamycin;

 

Chemical & Physical Properties:

Appearance: Yellow orange crystalline powder

Assay :≥98.0%

Density: 1.33 g/cm3

Boiling Point: 917.4℃ at 760 mmHg

Melting Point: 179-181℃ (dec.)

Flash Point: 508.6℃

Refractive Index: 1.605

Vapor Pressure: 0mmHg at 25℃

 

Safety Information:

HS Code: 2941903000

RTECS: KD1925000

Toxicity: LD50 in mice (mg/kg): 122 i.v.; 258 i.p.; 3000 orally (Sensi, 1964)


The rifamycins are a group of chemically related antibioticsobtained by fermentation from cultures of Streptomycesmediterranei. They belong to a class of antibiotics called theansamycins that contain a macrocyclic ring bridged acrosstwo nonadjacent positions of an aromatic nucleus. The termansa means “handle,” describing well the topography of thestructure. The rifamycins and many of their semisynthetic derivativeshave a broad spectrum of antimicrobial activity.They are most notably active against Gram-positive bacteriaand M. tuberculosis. However, they are also active againstsome Gram-negative bacteria and many viruses. Rifampin, asemisynthetic derivative of rifamycin B, was released as anantitubercular agent in the United States in 1971. A secondsemisynthetic derivative, rifabutin, was approved in 1992 forthe treatment of atypical mycobacterial infections.


If you are interested in our products or have any questions, please feel free to contact us!


Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.